<DOC>
	<DOCNO>NCT00068315</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bortezomib give together fludarabine without rituximab treat patient relapsed refractory indolent non-Hodgkin 's lymphoma chronic lymphocytic leukemia . Bortezomib may stop growth cancer cell block enzymes necessary cancer cell growth . Drugs use chemotherapy , fludarabine , work different way stop cancer cell divide stop grow die . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving bortezomib together fludarabine without rituximab may kill cancer cell .</brief_summary>
	<brief_title>Bortezomib Fludarabine With Without Rituximab Treating Patients With Relapsed Refractory Indolent Non-Hodgkin 's Lymphoma Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity bortezomib fludarabine without rituximab patient relapse refractory indolent non-Hodgkin 's lymphoma chronic lymphocytic leukemia . II . Determine maximum tolerate dose bortezomib combination fludarabine patient . III . Determine biological effect regimen apoptotic marker , cell cycle kinase inhibitor , DNA repair patient . OUTLINE : This multicenter , dose-escalation study bortezomib . Patients receive bortezomib IV 3-5 second day 1 , 4 , 8 , 11 fludarabine IV 30 minute day 1-3 1-5 . Patients may also receive rituximab IV 1 hour day 1 . Treatment repeat every 3 week 8 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bortezomib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diagnosis chronic lymphocytic leukemia ( CLL ) OR indolent nonHodgkin 's lymphoma ( NHL ) follow subtypes : Follicular lymphoma : Grade I follicular small cleave cell ; Grade II follicular mixed cell ; Grade II follicular large cell ; Diffuse small cleave cell ; Small lymphocytic lymphoma ; Lymphoplasmacytic lymphoma ( Waldenstrom 's macroglobulinemia ) AND Extranodal marginal zone Bcell lymphoma ( mucosaassociated lymphoid tissue [ MALT ] lymphoma ) ; Nodal marginal zone Bcell lymphoma ( monocytoid Bcell lymphoma ) ; Splenic marginal zone lymphoma ( splenic lymphoma villous lymphocyte ) ; Mantle cell lymphoma : No blastic phase mantle cell lymphoma Relapsed refractory , progressive disease : First , second , third relapse Measurable disease , meet 1 follow criterion : At least 1 unidimensionally measurable lesion least 20 mm conventional technique OR least 10 mm spiral CT scan ( NHL patient ) ; OR : Lymphocytosis &gt; 50,000/mm3 OR evidence progressive bone marrow infiltration failure ( e.g. , hemoglobin 10 g/dL ) OR thrombocytopenia ( i.e. , platelet count &lt; 100,000/mm3 ) &gt; 30 % infiltration bone marrow leukemia ( CLL patient ) No measurable lymphadenopathy ( CLL Waldenstrom 's macroglobulinemia patient ) No evidence CNS lymphoma Performance status : ECOG 02 Life expectancy : More 12 week No history uncontrolled orthostatic hypotension No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No uncontrolled concurrent illness No grade 2 great neuropathy No history allergy anaphylaxis mannitol , bortezomib , fludarabine , boron No ongoing active infection No psychiatric illness social situation would preclude study compliance At least 4 week since prior monoclonal antibody ( MoAB ) therapy : Patients receive MoAB therapy within past 3 month must document disease progression since receive therapy No prior allogeneic stem cell transplantation More 4 week since prior chemotherapy Prior fludarabine allow At least 1 week since prior steroid At least 3 month since prior radioimmunotherapy More 4 week since prior radiotherapy No prior bortezomib Absolute neutrophil count least 1,500/mm3 Platelet count least 75,000/mm3 ( great 50,000/mm3 lymphomatous bone marrow involvement present ) Bilirubin great 2.0 mg/dL AST/ALT great 4 time normal Creatinine clearance great 40 mL/min No concurrent investigational agent treatment malignancy No brain metastases OR : Quantitation IgM paraprotein ( Waldenstrom 's macroglobulinemia patient )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>